Latest research on Zytiga

Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.

Latest findings

This has led to numerous research efforts focusing on the development of inhibitors that interfere with key enzymes, such as cytochrome P450 17A1 (CYP17A1), in androgen biosynthesis as exemplified by the recent FDA approval of abiraterone (Zytiga). [source, 2014]
Two potentially attractive candidates are Zytiga and Gilenya (Figure 5B), both of which bear structural resemblance to natural metabolites and are prohibitively expensive, with an estimated annual cost of $40000 per patient. [source, 2014]
Another treatment emerged in the same year, as a second line hormonal therapy abiraterone (Zytiga) passed a phase III trial for CRPC patients who had failed chemotherapy. [source, 2013]
In April 2011, abiraterone (Zytiga, Johnson & Johnson/Cougar) was approved for castration-resistant prostate cancer. [source, 2013]
Through the identification of the molecular mechanisms promoting AR signaling in the setting of castration (AR amplification, AR over expression, AR mutation, peripheral androgen production) a number of novel therapies (enzalutamide, Zytiga) have successfully been developed and have been shown to improve survival in patients with castrate resistant disease (5-8). [source, 2013]
Improved, specific CYP17A1 inhibitors such as abiraterone (Janssen) FDA, TAK-700 (Takeda/Millenium Pharmaceuticals), and TOK-001 (Tokai Pharmaceuticals) are now in various stages of clinical assessment for adjuvant use with LHRH agonists. abiraterone, unlike previous CYP17 inhibitors, has a 3-pyridyl substitute and 16,17 double bond, which makes it a highly specific, potent, and irreversible inhibitor of both the hydroxylase and lyase activity of CYP17A1 [131–133]. abiraterone acetate, the oral drug precursor of abiraterone, has been FDA approved with trade named Zytiga for CRPC treatment, in settings of postdocetaxel [134] and now prechemotherapy [135]. [source, 2013]
Within a course of less than 2.5 years, four new therapeutic modalities became available to patients with castration-resistant prostate cancer in the post-docetaxel setting: the taxane cabazitaxel (Jevtana), the immunotherapeutic sipuleucel-T (Provenge), the CYP17 inhibitor abiraterone acetate (Zytiga), and the second-generation AR antagonist enzalutamide (XTANDI). [source, 2013]
One promising drug approved by the Food and Drug Ad-ministration (FDA) in 2011 for treatment of metastatic castration-resistant prostate cancer is abiraterone (Zytiga). [source, 2013]
The success in phase III clinical trials of abiraterone acetate (Zytiga), a 17α-hydroxylase/17,20-lyase inhibitor, and its subsequent approval by the FDA support the involvement of adaptive androgen biosynthesis within the tumor in CRPC. [source, 2013]
Abiraterone acetate (Zytiga, Janssen/Ortho-Biotech, Horsham, PA) is an inhibitor of CYP17 that functions as an androgen biosynthesis inhibitor that is currently approved in both pre- and postdocetaxel setting of mCRPC. [source, 2013]